Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/5182

Title: Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis
Authors: Buyse, Marc E.
Thirion, Pierre
Carlson, Robert W.
Burzykowski, Tomasz
Molenberghs, Geert
Piedbois, Pascal
Issue Date: 2000
Publisher: LANCET LTD
Citation: The lancet, 356(9227). p. 373-378
Abstract: Background Treatment of advanced colorectal cancer has progressed substantially. However, improvements in response rates have not always translated into significant survival benefits. Doubts have therefore been raised about the usefulness of tumour response as a clinical endpoint. Methods This meta-analysis was done on individual data from 3791 patients enrolled in 25 randomised trials of firstline treatment with standard bolus intravenous fluoropyrimidines versus experimental treatments (fluorouracil plus leucovorin, fluorouracil plus methotrexate, fluorouracil continuous infusion, or hepatic-arterial infusion of floxuridine). Analyses were by intention to treat. Findings Compared with bolus fluoropyrimidines, experimental fluoropyrimidines led to significantly higher tumour response rates (454 responses among 2031 patients vs 209 among 1760; odds ratio 0·48 [95% CI0·40–0·57], p<0·0001) and better survival (1808 deaths among 2031 vs 1580 among 1760; hazard ratio 0·90 [0·84–0·97], p=0·003). The survival benefits could be explained by the higher tumour response rates. However, a treatment that lowered the odds of failure to respond by 50% would be expected to decrease the odds of death by only 6%. In addition, less than half of the variability of the survival benefits in the 25 trials could be explained by the variability of the response benefits in these trials. Interpretation These analyses confirm that an increase in tumour response rate translates into an increase in overall survival for patients with advanced colorectal cancer. However, in the context of individual trials, knowledge that a treatment has benefits on tumour response does not allow accurate prediction of the ultimate benefit on survival.
URI: http://hdl.handle.net/1942/5182
DOI: 10.1016/S0140-6736(00)02528-9
ISI #: 000088486000009
ISSN: 0140-6736
Category: A1
Type: Journal Contribution
Validation: ecoom, 2001
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
Published version123.47 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.